Inspecs GroupINPEF 52 Return-on-Tangible-Equity is -103.76% as of Dec. 2025. GuruFocus rates INPEF with a GF Score™ of 52/100 and a GF Value™ of $0.65. The stock has 6 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Inspecs Group ranks worse than 86.71% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Inspecs Group's annualized net income for the quarter that ended in Dec. 2025 was $-13.2 Mil. Inspecs Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $12.8 Mil. Therefore, Inspecs Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -103.76%.
The historical rank and industry rank for Inspecs Group's Return-on-Tangible-Equity or its related term are showing as below:
INPEF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -106.41 Med: -34.55 Max: 35.81
Current: -93.03
During the past 10 years, Inspecs Group's highest Return-on-Tangible-Equity was 35.81%. The lowest was -106.41%. And the median was -34.55%.
INPEF's Return-on-Tangible-Equity is ranked worse than 86.71% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.115
vs INPEF: -93.03
Inspecs Group (OTCPK:INPEF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Inspecs Group Return-on-Tangible-Equity Related Terms
Inspecs Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Inspecs Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INPEF vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Inspecs Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -103.76% mean?
Inspecs Group (INPEF) has a Return-on-Tangible-Equity of -103.76% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Inspecs Group and its competitors. According to the industry distribution chart, Inspecs Group ranks #659 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 86.7%.
Is Inspecs Group's Return-on-Tangible-Equity too high?
Inspecs Group's current Return-on-Tangible-Equity is -103.76%. Based on the distribution chart, Inspecs Group ranks #659 out of 760 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Inspecs Group has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Inspecs Group ranks #659 out of 760 companies for Return-on-Tangible-Equity. This places Inspecs Group in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.12, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Inspecs Group and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspecs Group's current Return-on-Tangible-Equity is -103.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Inspecs Group (INPEF) has a current Return-on-Tangible-Equity of -103.76%. The stock's GF Value™ is $0.65, compared to a current price of $1.08 — trading 66.2% above its estimated fair value. The current Return-on-Tangible-Equity is -103.76%. Inspecs Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Inspecs Group (INPEF), the current Return-on-Tangible-Equity is -103.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (INPEF) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of $1.08 is trading 66.2% above its estimated GF Value™ of $0.65.
Key valuation signals for INPEF:
Return-on-Tangible-Equity: -103.76%
GF Value™: $0.65 vs. price of $1.08 (66.2% above fair value)
No single metric tells the full story. See the INPEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
52GF Score
Get the complete analysis for INPEF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INPEF has been successfully added to your 
